Leading Animal Stem Cell Developer MediVet-America Achieves Significant Business Growth Milestones in First Year

News provided by

Feb 04, 2011, 04:13 ET

NICHOLASVILLE, Ky., Feb. 4, 2011 /PRNewswire/ -- MediVet-America, the leading developer of in-clinic stem cell regenerative therapy for animals suffering from osteoarthritis, hip dysplasia, ligament and cartilage injuries and similar ailments, ended its first year of business having achieved record advances in size and scope.

Using MediVet-America's new Adipose-Derived Stem Cell Procedure Kit and equipment, veterinary practitioners perform the drug-free procedure entirely in their own clinics, in one day, more quickly, effectively and economically than first-generation animal stem cell therapy.

This new treatment, previously only available in Australia and New Zealand, was launched in the United States, Canada, South America and Hong Kong in 2010.

Over the past year, MediVet-America has signed agreements with more than 100 leading veterinarians and clinics, 12 distributor territories in 20 states and four provinces in Canada, providing vets with the ability to perform in-house stem cell procedures that can lengthen and rejuvenate the quality of life for adult dogs, cats and horses experiencing lameness, pain, and a restricted range of motion. Before stem cell therapy, veterinarians were limited to prescribing anti-inflammatory medicine or performing expensive surgery.

In December, the company launched MediVet Lab Services in Lexington, KY, that provides technical support for in-clinic animal stem cell procedures, regional and national Adipose Stem Cell Processing, Cryogenic Banking Services, Autologous Conditional Serum Processing, and Cell Counting Services for stem cell treatments.

MediVet-America Managing Director Jeremy Delk envisions opening additional labs throughout the U.S. that will also provide an interactive web site with an online vet certification program and a quality assurance/control program encompassing cell counts and sterility.

"We experienced a tremendous year of growth in all areas of our business," said Delk. "We're overwhelmed by the enthusiastic response we've received from pet owners and veterinarians around the world, and we're deeply honored by the pet industry's acknowledgement of our services.

"Excitement for the technology continues to grow; we are now seeing stem cell procedures happening every day for the past two months."

ABOUT MEDIVET-AMERICA

A research and development company and global leader in veterinary stem cell technology, MediVet-America provides innovative cell applications for the therapeutic care of animals. Headquartered in Nicholasville, Kentucky, MediVet-America develops advanced cellular designed kits and services for the treatment of osteoarthritis and degenerative joint disease. www.MediVet-America.com